Table 33, Summary of included studies. Comparison 32. Switching to bupropion versus placebo - Further-line treatment

Warning: The NCBI web site requires JavaScript to function. more...

Study	Population	Intervention	Comparison	Details of inadequate response/treatment resistance	Comments
GlaxoSmithKline 2009 RCT Japan	N=325 Mean age (years): 36.4 Gender (% female): 45 Ethnicity (% BME): NR Baseline severity: HAMD 19.6 (more severe)	Bupropion hydrochloride sustained release 100-300mg/day	Placebo	Inadequate response to paroxetine (20-40 mg/day) for 4 weeks	Treatment length (weeks): 12 Outcomes: Depression symptomatology change score Remission Response Discontinuation due to any reason Discontinuation due to side effects

Study

Population

Intervention

Comparison

Details of inadequate response/treatment resistance

Comments

RCT

Japan

N=325

Mean age (years): 36.4

Gender (% female): 45

Ethnicity (% BME): NR

Baseline severity: HAMD 19.6 (more severe)

Bupropion hydrochloride sustained release 100-300mg/day

Placebo

Inadequate response to paroxetine (20-40 mg/day) for 4 weeks

Treatment length (weeks): 12

Outcomes:

: BME: black and minority ethnic; HAMD: Hamilton depression scale; NR: not reported; RCT: randomised controlled trial

Further-line treatment: Depression in adults: Evidence review D.

NICE Guideline, No. 222.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.